. Author manuscript; available in PMC: 2022 Aug 10.

Published in final edited form as: Clin Adv Hematol Oncol. 2021 Sep;19(9):573–581.

Table 2.

Selected Systemic Therapies Used for Cutaneous T-Cell Lymphomas

Medication	Authors	N	ORR, %	DOR
Bexarotene	Duvic et al²⁴	56	45 (300 mg/m²)	299 d
Vorinostat	Olsen et al³⁵	74	30	≥185 d (estimated median DOR NR)
Romidepsin	Whittaker et al³³ Piekarz et al³⁴	96 71	34 34	15 mo 13.7 mo
Pralatrexate	Horwitz et al⁴²	54	45	NR
Brentuximab vedotin vs physician’s choice (methotrexate or bexarotene)	Prince et al³⁶	128 (64 vs 64)	67 vs 20	15.1 vs 18.3 mo
Mogamulizumab vs vorinostat	Kim et al³⁷	372 (186 vs 186)	28 vs 5	14.1 vs 9.1 mo

d, days; DOR, duration of response; mo, months; NR, not reached; ORR, overall response rate.